REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

04/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231204:nRSD4549Va&default-theme=true

RNS Number : 4549V  OptiBiotix Health PLC  04 December 2023

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Directorate change

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that Graham Myers has been appointed as Finance Director of the
Company as of 1 December 2023.

 

Graham is a member of the Institute of Chartered Accountants in England &
Wales and has extensive financial and commercial experience in a number of
private and public companies, including being a member of the Executive
Committee at Croda International Plc, where he worked for almost 30 years.
Graham brings extensive experience in optimising financial controls, managing
budgets, building profitable businesses and mergers & acquisitions. Graham
is currently Chair of Croda Pension Trustees Limited, the sole trustee of
Croda's £800m UK pension scheme.

 

Graham's appointment to this part-time role will see him work closely with the
OptiBiotix team to support the focus on driving each business unit and the
Group to profitability.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Graham Lloyd Myers (aged 60):

 

 Current Directorships           Previous Directorships held in the past five years
 Croda Pension Trustees Limited  Bio Futures PI Limited
 Croda Trustees Limited          Cargill Bioindustrial BV (Previously Croda Nederland BV)
                                 Cowick Insurance Services Limited
                                 Croda (Thailand) Co Ltd
                                 Croda Cosmetics & Toiletries Limited
                                 Croda Food Services Limited
                                 Croda India Company Private Limited
                                 Croda Investments Limited
                                 Croda Investments No 2 Limited
                                 Croda Investments No 3 Limited
                                 Croda Overseas Holdings Limited
                                 Croda Polymers International Limited
                                 Croda World Traders Limited
                                 Enza Biotech AB
                                 Lanxess Urethanes UK Ltd
                                 P. I. Bioscience Limited
                                 Plant Impact Limited
                                 PT. Croda Indonesia LLC
                                 Uniqema Limited
                                 Uniqema UK Limited

 

Graham Myers holds no ordinary shares, options or warrants over ordinary
shares in the Company.

 

There is no further information regarding Graham Myers required to be
disclosed under the AIM Rules.

 

Stephen OHara, CEO of OptiBiotix commented: "We are pleased to confirm the
appointment of Graham Myers as Finance Director. The appointment reflects the
progress we have made in 2023 after a difficult 2022 and the Board's focus on
controlling costs and building revenues to create a profitable international
business with well-known global brands".

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Joint Broker)         Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reflect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEFLFBXLLEFBF